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Highlights: 
? The risk of Alzheimer’s disease was almost 4-fold higher in cases of clinically relevant anxiety 
compared with non-cases, even when controlling for depression and other potential 
confounders. 
? This finding may stimulate future studies to test the impact of the treatment of anxiety on 
prevention or delay onset of symptoms of AD. 
? The association between subcases of anxiety at baseline and AD risk did not reach statistical 
significance. 
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Abstract 
 
Objectives: To investigate whether clinically relevant anxiety increased the risk for 
developing Alzheimer’s disease (AD) while controlling for the presence of depression 
and other confounders; and to report the population attributable fraction (PAF) 
associated with anxiety disorder. 
 
Method: We used data from the longitudinal, community-based Zaragoza Dementia and 
Depression (ZARADEMP) study. A random sample of 4,057 dementia-free community 
dwellers aged 55 or older were followed for 4.5 years. The Geriatric Mental State-
Automated Geriatric Examination for Computer Assisted Taxonomy package was used 
for the diagnosis of clinically significant cases and subcases of anxiety; and AD was 
diagnosed by a panel of research psychiatrists according to DSM-IV criteria. 
Multivariate survival analysis with competing risk regression model was performed. 
 
Results: We observed a significant association between anxiety cases at baseline and 
AD risk in the univariate analysis that persisted in the fully adjusted model (SHR: 3.90; 
95% CI: 1.59 - 9.60; p=0.003), with a PAF for AD of 6.11% (95% CI: 1.30% - 16.17%). 
No significant association between ‘subcases’ of anxiety at baseline and AD was found.  
 
Limitations: Data on apolipoprotein E were not available. The hospital-based diagnosis 
was not completed in all cases of dementia. 
 
Conclusion: Late life, clinically significant anxiety (but not subclinical anxiety) seems to 
increase the risk of AD, independently of the effect of several confounders, including 
depression. Taking into account the high prevalence of anxiety among the elderly, 
future studies are warranted to determine potential risk reduction of AD. 
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Introduction 
The analysis of risk reduction of dementia and its most frequent type, Alzheimer disease 
(AD), has been put at stake in a report (Wortmann, 2014) which includes classical modifiable 
risk factors (lifestyle and cardiovascular factors) but also psychological factors such as 
depression and anxiety. While the association of depression and AD has been extensively 
investigated in the last years (Cherbuin et al., 2015), the study of the link between anxiety 
and AD has only started to be on the spotlight. A recent meta -analysis (Becker et al., 2018) 
reports that subjects presenting with anxiety have a 53% higher risk for AD, thus postulating 
anxiety as a potential risk factor for AD. However, the majority of measures used to identify 
cases of anxiety in the articles included in this meta–analysis have been considered to lack 
sufficient evidence to warrant their use with older individuals (Therrien & Hunsley, 2012). 
Since we have shown that clinically relevant anxiety increases the risk of overall dementia 
(Santabárbara et al., 2018), we now hypothesize that it also is associated with increased AD 
risk. A second objective was to report the population-attributable fraction (PAF) of AD due 
to anxiety disorder. 
Method 
Sample and Procedure 
We used data from the Zaragoza Dementia and Depression (ZARADEMP) project, a 
longitudinal, population-based study intended to document the incidence and risk factors of 
somatic and psychiatric diseases in adults aged ≥55 years (Lobo et al., 2005). The sample 
was drawn from Spanish official census lists, included institutionalized individuals and was 
stratified with proportional allocation by age and sex. Refusal rate was 20.5%, and 4,803 
individuals finally participated at baseline (starting in 1994). A two-phase, screening 
procedure was implemented in the baseline (Wave I) and in the two follow-up waves (Waves 
II and III) completed for this study. Validated, Spanish versions of international instruments 
were used for the assessment: the Mini-Mental Status Examination (MMSE); the Geriatric 
Mental State B (GMS-B); the Automated Geriatric Examination for Computer Assisted 
Taxonomy (AGECAT) (Copeland et al., 1986 ); the History and Aetiology Schedule (HAS) 
(medical and psychiatric history data); the Katz’s Index for basic activities of daily living 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
6 
 
(bADL’s) and the Lawton and Brody scale for instrumental activities (iADL’s); and the 
European Studies of Dementia (EURODEM) Risk Factors Questionnaire (for medical 
conditions). A more detailed account of the methods has been reported previously (Lobo et 
al., 2011; Santabarbara et al, 2018).  
The Ethics Committee of the University of Zaragoza and the Fondo de Investigación 
Sanitaria (FIS) approved the study, according to Spanish Law, and principles of written 
informed consent, privacy, and confidentiality have been maintained throughout the Project. 
Alzheimer’s Disease assessment and diagnosis 
At the end of the baseline assessment, identified cases of dementia and subcases of dementia 
(GMS –criteria) were excluded for the follow-up waves (II and III). Incident dementia 
(including subtypes) was initially diagnosed at follow-up by a psychiatrist and the final AD 
DSM-IV diagnosis was made by consensus that required agreement of at least three 
psychiatrists in a four- member panel. The validity of this diagnostic process has also been 
shown (Lobo et al., 1995). To document the accuracy of the panel, some detected cases were 
invited to a hospital diagnostic work- up, and NINCDS-ADRDA criteria were applied to 
diagnose AD. Agreement on the diagnosis of dementia and type of dementia was reached in 
95.8% and 87.5% of the cases, respectively.  
Anxiety Assessment and Diagnosis 
Anxiety diagnosis was based on the GMS-AGECAT. This diagnostic approach has been 
shown to be valid in community samples, and participants with AGECAT confidence levels 
? 3 in the 0–5 scale are considered to be likely ‘cases’ of clinically significant anxiety 
requiring clinical intervention (Copeland et al., 2004). The diagnosis of subsyndromal 
anxiety (“subcase”, confidence levels 1 and 2) implies that the clinical symptoms are not 
severe enough to require an intervention. 
Covariates 
The following covariates were used: socio-demographic characteristics (age, sex, educational 
level, marital status and living alone), medical risk factors (vascular disease, hypertension 
and diabetes), health status, cognitive status and clinically significant depression. 
(Santabárbara et al., 2018) 
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Statistical analysis 
We used the Fine and Gray multivariate regression model to calculate the risk of participants 
for experiencing AD, taking into account the competing event (death) as time progressed and 
with age as timescale with delayed entry (Thiébaut & Bénichou, 2004). 
We estimated the population-attributable fraction (PAF) for AD which might be related to 
anxiety status and the 95% CI. The PAF tries to estimate the proportion of AD risk that 
would be avoided if the condition (anxiety) could be prevented, assuming a causal effect and 
unbiased estimates. 
Statistical analyses were conducted using R software (http://www.r-project.org).  
Results 
Supplementary Figure 1 illustrates the flow diagram of the ZARADEMP Project. The 
refusal rate was 20.5%, and 4803 individuals were ultimately interviewed at baseline 
(ZARADEMP I). Subjects with dementia and subcases of dementia (n=746) were 
excluded from the two follow-up evaluations (ZARADEMP II and ZARADEMP III). 
Then, our final sample included 4057 participants without any type of dementia for the 
4.5-years follow-up period (median 4.4 years; interquartile range: 3.0- 4.9 years). 
Baseline characteristics according to anxiety status have been described elsewhere 
(Santabárbara et al., 2018). In brief, compared with subcases and non-cases, cases of 
anxiety were more likely to be female, to report bad health status, and to have depression 
and disabilities for instrumental ADLs. 
Table 1 shows initial demographic characteristics according to AD incidence status. The 
incident AD group was significantly older, more likely to be female, illiterate, widowed, 
to perform worse cognitively and to have anxiety and functional disabilities. During the 
4.5 years follow-up period, 730 (17.9%) individuals died and 849 (20.9%) were lost 
(Supplementary figure 1). Those lost during follow-up were on average 4.3 years older (p 
< 0.001) and more likely to be illiterate than those re-evaluated; the MMSE scores were 
also lower among those lost (p < 0.001). 
The proportion of incident cases of AD increased according to the severity of the anxiety 
status (Table 2): 1.8% for non-cases, 2.3% for subcases and 6.6% for cases (p for trend = 
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0.038). Table 2 also shows the results of the competing risk regression analysis of AD 
incidence associated with anxiety status at baseline. The risk of AD was almost 4-fold 
higher in anxiety cases compared with noncases when all potential confounding factors 
were controlled (HR: 3.90; 95% CI: 1.59–9.60). No significant association between 
‘subcases’ of anxiety at baseline and AD was found in either model. 
We estimated that the proportion of the population with anxiety was 2.24%. This yields a 
PAF for AD of 6.11% (95% CI: 1.30% -16.17%). 
Discussion 
Our findings in a sample of community-dwelling adults aged 55+ showed that, compared 
with subjects without anxiety, the incidence rate of AD during a period of 4.5-years was 
3.9 -fold higher among individuals with clinically relevant anxiety, after adjusting for 
several covariates, including depression. By contrast, this association was not found for 
subjects with subthreshold anxiety. The PAF documented in this study suggests the 
possible contribution of anxiety in a considerable proportion of cases (6.1%) to the 
development of AD in the entire population (Porta, 2008). To our knowledge, this is the 
first study addressing the effect of clinically relevant anxiety on the risk of AD. 
Our results agree with recent meta-analysis indicating a positive and significant 
association between anxiety and AD in older adults (Becker et al., 2018). However, the 
magnitude of effect found in our sample was higher, suggesting the importance of using 
clinical criteria for anxiety. De Bruijn et al (2014) did not find a significant association 
with AD neither in clinical anxiety (according to DSM criteria) nor in anxiety symptoms 
in a large community sample of older adults despite controlling for the confounding effect 
of APOE-4; however, they did not adjust for the competing risk of death which might 
explain the discrepancies between both studies.  
Similar to depression, there is still debate on whether anxiety is a risk factor for AD or it 
is an early sign of an underlying neurodegenerative process. A recent systematic review 
(Gimson et al, 2018) reports a positive association between anxiety and risk of dementia 
over a mean interval of at least 10 years, suggesting that anxiety at midlife is associated 
with dementia and thus supporting the idea that anxiety is a risk factor rather than a 
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prodromal state. While our follow-up period was only 4.5 years, our findings also support 
the notion of increased risk as opposed to prodromal feature, for several reasons. First, to 
minimize the possibility of including in the cohort individuals with cognitive deficits at 
baseline, we excluded at baseline all “subcases” of cognitive impairment or dementia 
(AGECAT criteria) to minimize the possibility of including in the cohort individuals with 
mild or very mild cognitive deficits.. Second, cognitive status at baseline was controlled in 
the analysis. Third, it might be argued that individuals with subclinical anxiety were in 
fact incipient, prodromal cases of AD (Forsell et al., 1993). However, only clinically 
significant anxiety, but not subclinical anxiety, was associated with AD. If anxiety was 
prodromic, it would be expected that anxiety subcases would also develop dementia in a 
4.5-year period. 
Some cojectures may help to explain the increased risk of AD associated with anxiety 
disorder. Anxiety during lifetime can compromise neuroplasticity and reduce cognitive 
reserve (Vance et al, 2010). In addition, anxiety could share etiological underlying 
mechanisms with AD. Some studies (Salim et al., 2012) postulate anxiety as a behavioural 
consequence of inflammation and oxidative damage to the central nervous system (CNS). 
Similarly, there is growing evidence for the role of CNS inflammation in the continuum of 
the AD pathology (Cuello et al., 2017), which starts at very early stages, most likely before 
amyloid plaques are formed. Moreover, recent studies suggest a bi-directional association 
between amyloid-β (Aβ) and anxiety. High anxiety levels in Aβ+ individuals have been 
found to be associated with faster cognitive decline (Pietrzak et al, 2015), and higher 
amyloid beta burden to be associated with increasing anxious-depressive symptoms over 
time in cognitively normal older individuals (Donovan et al, 2018 ). 
Our results also suggest that the association between anxiety in older adults and AD is 
independent from several confounders, including education, cognitive status, medical 
conditions and particularly depression. Depression has been consistently associated with 
increased risk for AD (Gracia-García et al, 2013). Thus, our findings would support the idea 
that anxiety is acting on the brain through pathways different than depression. This warrants 
future research. 
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Our study had several strengths, including a representative population sample, containing 
institutionalized individuals, a longitudinal design, the use of high sensitivity and specificity 
of case finding with validated instruments, the use of age as timescale, and the inclusion of 
actual mortality data in the Fine and Gray model to study anxiety as a risk factor for AD. 
Furthermore, this was the first investigation using a competing risk model to study anxiety as 
a risk factor for AD, which estimates risk more accurately than traditional models (e.g., 
Kaplan-Meier and Cox regression) (Berry et al., 2010). 
Limitations 
Among the limitations, we should mention the small number of subjects with clinically 
significant anxiety that developed AD, the absence of data on apolipoprotein E, and the fact 
that the hospital-based diagnosis was not completed in all cases of dementia. Furthermore, 
we did not control for family history of AD, excessive alcohol intake, smoking and the use of 
psychotropic medication. Medications with positive effect on anxiety symptoms could 
influence the results in several ways. Moreover, some studies have associated the use of 
psychotropic medication with a higher risk of dementia (Shash et al., 2015), but other authors 
(Burke et al., 2016) argue that anxiolytics might neutralize the hazard of development AD 
associated with anxiety. The lost individuals in the sample were older and with lower MMSE 
scores, being theoretically at a higher risk of developing AD. However, we trust this has not 
influenced importantly the results. It is apparent that some individuals with incident AD may 
have been lost before they could be examined at follow-up, and therefore we do not know 
their anxiety status at baseline. The main reason for losses in this study has been the 
mortality, and could also be related to the low MMSE and associated disability. Previous 
reports have documented in older individuals the association of anxiety with cognitive 
decline (Gulpers et al, 2016), disability (Kang et al, 2017) and also with an increased 
mortality (Miloyan et al, 2016). Therefore, it might be expected that the onset of severe 
cognitive decline and probably AD, or the mortality would occur in a higher proportion of 
the anxiety cases than in the non-cases. Had these losses not happened, there would be more 
incident cases of AD among the anxiety cases. In such circumstances, the conclusions of this 
study would be reinforced. Finally, age at baseline was not included in the analysis as a 
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covariate. However, we used a different approach, with age as timescale to avoid biased 
estimates (Thiébaut & Bénichou, 2004). 
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Conclusion 
In conclusion, clinically significant anxiety, but not sub-clinical anxiety, was associated with 
AD risk in these study subjects, even after controlling for confounding factors. Although 
causal relations cannot be established with certainty, this finding may stimulate studies about 
the possibility of intervening on anxiety to prevent or delay the development of AD. Future 
research is also needed to understand mechanisms involved in the association of anxiety and 
AD risk. 
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TABLES 
Table 1. Baseline characteristics according to incident AD status 
 
No AD 
(N = 3968) 
Incident AD  
(N = 87) 
p-value 
Age (years) 72.83 (9.03) 83.72 (7.13) <0.001 
Female sex 2168 (54.6%) 61 (70.1%) 0.004 
Education    
 Primary school 2960 (75.2%) 59(67.8%) <0.001 
 High school or higher 681 (17.3%) 9 (10.3%)  
Civil status    
 Married/in couple 2501 (63.2%) 27 (31.0%) <0.001 
 Divorced/separated 57 (1.4%) 1 (1.1%)  
 Widowed 1037 (26.2%) 57 (65.5%)  
Living alone 689 (17.4%) 12 (13.8%) 0.385 
MMSE 27.27 (2.52) 24.46 (2.47) <0.001 
Anxiety  1,607 (40.5%)  38 (43.7%) 0.008 
   Subcase 85 (2.1%) 6 (6.9%)  
   Case    
Depression 442 (11.1%) 13 (14.9%) 0.265 
Disability    
 Instrumental ADLs 479 (12.1%) 33 (37.9%) <0.001 
 Basic ADLs 263 (6.6%) 14 (16.1%) 0.001 
Health status (‘not good’) 2052 (51.7%) 49 (57.0%) 0.336 
Vascular risk factors    
 Hypertension 2692 (67.9%) 55 (63.2%) 0.354 
 Diabetes 491 (12.5%) 10 (11.6%) 0.814 
 Vascular disease 449(11.3%) 10 (11.5%) 0.959 
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 Notes: Data are given as mean (standard deviation) or number (%). 
p values were from “normal approximation” of t test with 4,053 df and Wald χ2 test with 1 df (or 2 df for 
anxiety).  
ADLs = activities of daily living; MMSE = Mini-Mental State Examination. 
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Table 2. Anxiety status and risk of AD 
   Univariate Model  Multivariate Model 
Anxiety status at 
baseline 
 No. (%) of AD  
incident cases 
SHR (95% CI)a p-value  SHR (95% CI)a p-value 
       
Noncase (n=2321) 43 (1.8) 1 ―  1 ― 
Subcase (n=1645) 38 (2.3) 1.07 (0.70-1.64) 0.760  1.19 (0.75-1.88) 0.460 
Case (n=91) 6 (6.6) 3.20 (1.39-7.40) 0.006  3.90 (1.59-9.60) 0.003 
 Notes: SHR: Subdistribution Hazard Ratio. Bold entries mean the SHR is statistically significant. 
aReportedSHR of AD is related to noncases, CIs and p values related to SHR were from “normal approximation” of Wald χ2 test with 1 
df. Univariate Model include anxiety status and sex. Multivariate Model included terms from Model 1 plus sociodemographic 
characteristics (educational level, marital status, and living alone), medical risk factors (vascular disease, hypertension, and diabetes), 
health status, depression and cognitive status at baseline (MMSE). 
